Previous 10 | Next 10 |
home / stock / mdp:cc / mdp:cc news
TORONTO and CHICAGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Wednesday, November 9, 2022 to discuss Medexus’s results for its second quar...
TORONTO and CHICAGO, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce preliminary estimates of the company’s revenue results for the fiscal quarter ended September 30, 2022 (the company’s ...
Medexus’s borrowing capacity under its revolving credit facility increases by US$5.0 million, from US$20.0 million to US$25.0 million Transaction strengthens Medexus’s balance sheet, providing additional operating liquidity TORONTO and CHIC...
FDA requests further information from medac, continues to engage with treosulfan NDA Medexus continues to focus on maintaining momentum and growth in its North American on-market portfolio, and is now recognizing 100% of Gleolan U.S. net sales as of September Medexus to host li...
All director nominees reelected for the coming year All other proposals also approved by shareholders TORONTO and CHICAGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of sh...
TORONTO and CHICAGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Tuesday, August 9, 2022 to discuss Medexus’s results for its first quarter e...
FDA decision expected within six months of acceptance Pivotal phase 3 clinical trial of treosulfan met primary endpoint and key secondary endpoints TORONTO and CHICAGO, July 25, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: ...
TORONTO and CHICAGO, June 22, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company’s fourth fiscal quarter and fiscal year ended March...
TORONTO and CHICAGO, June 14, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, June 23, 2022 to discuss Medexus’s results for its fourth quarter ...
Study’s primary endpoint and key secondary endpoints were met Study found event-free survival and overall survival superior after treosulfan compared to RIC busulfan, also found non-relapse mortality lower in treosulfan arm than busulfan arm Study results accepted for publi...
News, Short Squeeze, Breakout and More Instantly...
Medexus Pharmaceuticals Inc. Company Name:
MDP:CC Stock Symbol:
TSXC Market:
Medexus Pharmaceuticals Inc. Website:
FDA has Accepted for Review the Treosulfan NDA Management to host conference call at 8:00 AM Eastern time on Wednesday, June 26, 2024 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 25, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and...
Lomiko Metals Inc. (LMR:CA) is expected to report for Q3 2024 Organto Foods Inc. (OGO:CA) is expected to report for Q1 2024 PreveCeutical Medical Inc. (PREV:CNX) is expected to report for Q1 2024 Blue Horizon Global Capital Corp Com (BHCC:CNX) is expected to report for Q1 2024 Per...
Evertz Technologies Limited (ET:CA) is expected to report $0.22 for Q4 2024 Transat A.T. Inc. Voting and Variable Voting Shares (TRZ:CA) is expected to report $-0.66 for Q2 2024 Medexus Pharmaceuticals Inc. (MDP:CA) is expected to report $-0.03 for Q4 2024 FP Newspapers Inc. (FP:CA) i...